Literature DB >> 1369271

A human-human hybridoma secreting anti-Pseudomonas aeruginosa exotoxin-A monoclonal antibody with highly potent neutralizing activity.

M Kuriyama1, Y Ichimori, S Iwasa, K Tsukamoto.   

Abstract

A hybridoma secreting human monoclonal antibody (MAB) against Pseudomonas aeruginosa exotoxin A (PEA) was constructed by fusing Epstein-Barr virus-transformed peripheral blood lymphocytes with human B lymphoblastoid cell line TAW-925. The human-human hybridoma stably produced human IgG2 MAB at the rate of 0.4-0.5 microgram/ml per 10(6) cells per day for more than six months, and the MAB was capable of neutralizing the in vitro cytotoxic and in vivo lethal effects of PEA with approximately 100- and 70-fold, respectively, higher activity than serum polyclonal antibody preparations.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1369271     DOI： 10.1007/BF00365263

Source DB:  PubMed          Journal:  Cytotechnology        ISSN： 0920-9069            Impact factor:   2.040


  17 in total

1.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.

Authors:  B H Iglewski; D Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

2.  Delineation of optimal conditions for producing mouse-human heterohybridomas from human peripheral blood B cells of immunized subjects.

Authors:  J L Butler; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

3.  Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique.

Authors:  D Kozbor; J C Roder
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

4.  Generation of human monoclonal antibodies reactive with cellular antigens.

Authors:  R J Cote; D M Morrissey; A N Houghton; E J Beattie; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

5.  Production of human hybridomas secreting antibodies to measles virus.

Authors:  C M Croce; A Linnenbach; W Hall; Z Steplewski; H Koprowski
Journal:  Nature       Date:  1980-12-04       Impact factor: 49.962

6.  Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.

Authors:  L Olsson; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

7.  Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa.

Authors:  S Sawada; T Kawamura; Y Masuho
Journal:  J Gen Microbiol       Date:  1987-12

8.  An improved colorimetric assay for interleukin 2.

Authors:  H Tada; O Shiho; K Kuroshima; M Koyama; K Tsukamoto
Journal:  J Immunol Methods       Date:  1986-11-06       Impact factor: 2.303

9.  Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A.

Authors:  J K Chia; M Pollack; D Avigan; S Steinbach
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.609

10.  Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa.

Authors:  D R Galloway; R C Hedstrom; O R Pavlovskis
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.609
View more
  2 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A.

Authors:  S Honda; Y Ichimori; S Iwasa
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.040
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.